Информационные ресурсы

PET modality is one of the most rapidly growing area of medical imaging thanks to the availability of innumerous clinical centers with their own cyclotrons. To be able to cover the growing clinical demands, radiopharmacies are developing new tracers while keeping up their routine production in a (c)GMP environment.  In this symposium, Dr. Ida Nymann Petersen, PhD. and Dr. Vasko Kramer, PhD.will share their experience in the development of new tracers on the Synthera® Platform.  When?  May 20th 4-5pm CET (Central European Time)   REGISTER What will you learn ?   Synthesis of [18F]mFBG and [18F]FE-PE2I on Synthera®+ platform By Dr. Ida Nymann Petersen, PhD., Radiochemist at Rigshospitalet in Copenhagen, Denmark.   In this talk, the fully automated labelling of [18F]mFBG and [18F]FE-PE2I on the Synthera®+ and Synthera®+ HPLC platform will be presented. [18F]FE-PE2I was synthesized in 32 % RCY, 98 % RCP in 40 min. [18F]mFBG is currently under optimization.    Development of new tracers: from neurology to oncology applications. By Dr. Vasko Kramer, PhD., Head of Research & Development at Positron Pharma in Santiago, Chile.  He will present some of their results for the production and development of new, innovative PET imaging agents for neurological ([18F]F-PR04.MZ, [18F]F-Florbetaben, [18F]F-PI-2620), oncological ([18F]FAPi-74, [18F]F-AlF-NOTA-Octreotide), and research applications (7-[18F]F-Fluoro-tryptophan, 18F-Tetrazines) using a compact, cassette-based synthesis platform.     You can join this symposium even if you don’t attend eSRS meeting.

Thank you  Dr. Jeremie Calais, Dr. Stefan Korber and Dr. Kai Schubert for your instructive presentations!  Did you miss the webinar? Watch the recording In addition to all questions answered at the end of this webinar, here are a few remaining ones, which the speakers kindly answered: Do you think that PET imaging in treatment position needs to be done systematically (in order to decrease irradiation dose exposure) ? Dr Calais: No. This is not like head and Neck or lung. Rectal and bladder filling are too complex to really have exact repositioning from PSMA PET to treatment table. Dr Schubert: Treatment position is not absolutely necessary, of course favorable. Different positions between treatment planning CT and ‘diagnostic’ imaging can be taken care of by deformable image registration, but there are limitations and additional QA would be necessary.   Is there any comparison between PSMA-Targeted therapy and SBRT?  Dr Calais :  No (not yet). Trials of PSMA MRT for oligometastatic disease are underway. My personal opinion is that it may not be the best application as a single agent therapy because the local control is inferior than with SBRT. However it can treat the microscopic and small lesions, so maybe the combination of both is probably a good approach.   When should we re-image after PSMA guided MDT? after changes in PSA? Dr Calais : At least 4 months after the end of SBRT ( for the local control).Otherwise if suspicion of new lesions based on PSA rise after NADIR or other imaging suspicion or clinical symptom. Dr Korber: I think, checking the PSA is adequate. Sure, if the PSA is rising again, new imaging (e.g. another PSMA-PET/CT) should be evaluated.

IBA invites you to attend a free webinar presented by 3 leading personalities in Nuclear Medicine, Radiation Oncology and Medical Physics: Dr Jeremie Calais, PD Dr. med. Stefan Körber and Dr. Kai Schubert.  In this webinar, the speakers will highlight the synergy between highly sensitive imaging, the definition of an intermediate stage between non-disseminated tumor and widespread metastatic disease (oligometastatic state) and high-precision radiation therapy (Stereotactic Body Radiation Therapy - SBRT) focused to treat the oligometastatic lesions. When? April 26th, 5-6 pm CET  REGISTER What will you learn from the webinar ?  •      Impact of PSMA PET on management of patients with oligo metastatic prostate cancer By Dr. Jeremie Calais, Director of the Clinical Research Program of the Nuclear Medicine and Theranostics Division at UCLA.  Dr Calais will cover the concept of oligometastatic disease in prostate cancer patients and the impact of PSMA PET imaging on the therapy management of those patients.   •    The Role of SBRT in the treatment of oligometastatic prostate cancer: Why & how SBRT for these patients By PD Dr. med. Stefan Körber,  First Senior Medical Doctor at Clinic for Radiation Oncology and Radiation Therapy at University Clinic of Heidelberg, Germany Dr. Körber will describe how the oligometastatic status of prostate cancer patients is defined on the basis of PSMA PET/CT and which strategies and modalities are applied for SBRT treatment of these patients    •    Quality assurance for SBRT treatments By Dr. Kai Schubert, Medical Physicist at Clinic for Radiation Oncology and Radiation Therapy at University Clinic of Heidelberg, Germany. The extremely high precision of SBRT requires an extensive program of Quality Assurance, both for the treatment machines as for the patient-specific treatment plans. Dr. Schubert will explain current strategies and future developments in this field.  REGISTER  

Did you miss the webinar about 68Ga-PSMA : from production to clinical applications? Watch the recordings   Thank you Prof. Francisco Alves and Dr. Jeremie Calais for your instructive presentations about Ga-PSMA: from production to applications. Here is a couple of questions that were answered during the Q&A:  How do you see the use of 66Ga for imaging? Could you clarify and give more information about; the minimal isotope composition of your enriched zinc-68, the impact in the impurity profile and the highest shelf-life that you can have?   Did you look at any correlation between PSA doubling time and velocity with the detection rate?  What’s the differences between FPSMA and Ga-PSMA?   For further information, you can read the published paper below.